186 related articles for article (PubMed ID: 38529509)
1. Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis.
Ippolitov D; Lin YH; Spence J; Glogowska A; Thanasupawat T; Beiko J; Del Bigio MR; Xu X; Wang A; Calvo R; Kapoor A; Marugan JJ; Henderson MJ; Klonisch T; Hombach-Klonisch S
bioRxiv; 2024 Feb; ():. PubMed ID: 38529509
[TBL] [Abstract][Full Text] [Related]
2. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
3. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
5. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
6. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo.
Liu H; Ruan S; Larsen ME; Tan C; Liu B; Lyu H
Biol Proced Online; 2023 Jun; 25(1):19. PubMed ID: 37370010
[TBL] [Abstract][Full Text] [Related]
8. Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies.
Miano C; Romaniello D; Mazzeschi M; Morselli A; Da Pra S; Sacchi F; Bongiovanni C; Sgarzi M; Pantano E; Lauriola M; D'Uva G
Front Oncol; 2022; 12():831105. PubMed ID: 35664762
[TBL] [Abstract][Full Text] [Related]
9. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
Cordero A; Ramsey MD; Kanojia D; Fares J; Petrosyan E; Schwartz CW; Burga R; Zhang P; Rashidi A; Castro B; Xiao T; Lee-Chang C; Miska J; Balyasnikova IV; Ahmed AU; Lesniak MS
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34969858
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
11. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
O'Shea J; Cremona M; Morgan C; Milewska M; Holmes F; Espina V; Liotta L; O'Shaughnessy J; Toomey S; Madden SF; Carr A; Elster N; Hennessy BT; Eustace AJ
Oncotarget; 2017 Oct; 8(49):85120-85135. PubMed ID: 29156708
[TBL] [Abstract][Full Text] [Related]
12. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
14. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Shawky H; Tawfik H
J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F
Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091
[TBL] [Abstract][Full Text] [Related]
16. Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Kalra R; Chen CH; Wang J; Salam AB; Dobrolecki LE; Lewis A; Sallas C; Yates CC; Gutierrez C; Karanam B; Anurag M; Lim B; Ellis MJ; Kavuri SM
Cancer Res; 2022 Aug; 82(16):2928-2939. PubMed ID: 35736563
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Kim JY; Lee E; Park K; Jung HH; Park WY; Lee KH; Sohn J; Lee KS; Jung KH; Kim JH; Lee KH; Im SA; Park YH
Int J Cancer; 2019 Sep; 145(6):1669-1678. PubMed ID: 30720867
[TBL] [Abstract][Full Text] [Related]
18. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Xu X; De Angelis C; Burke KA; Nardone A; Hu H; Qin L; Veeraraghavan J; Sethunath V; Heiser LM; Wang N; Ng CKY; Chen ES; Renwick A; Wang T; Nanda S; Shea M; Mitchell T; Rajendran M; Waters I; Zabransky DJ; Scott KL; Gutierrez C; Nagi C; Geyer FC; Chamness GC; Park BH; Shaw CA; Hilsenbeck SG; Rimawi MF; Gray JW; Weigelt B; Reis-Filho JS; Osborne CK; Schiff R
Clin Cancer Res; 2017 Sep; 23(17):5123-5134. PubMed ID: 28487443
[No Abstract] [Full Text] [Related]
19. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract][Full Text] [Related]
20. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.
Sperduto PW; Mesko S; Li J; Cagney D; Aizer A; Lin NU; Nesbit E; Kruser TJ; Chan J; Braunstein S; Lee J; Kirkpatrick JP; Breen W; Brown PD; Shi D; Shih HA; Soliman H; Sahgal A; Shanley R; Sperduto W; Lou E; Everett A; Boggs DH; Masucci L; Roberge D; Remick J; Plichta K; Buatti JM; Jain S; Gaspar LE; Wu CC; Wang TJC; Bryant J; Chuong M; Yu J; Chiang V; Nakano T; Aoyama H; Mehta MP
Neuro Oncol; 2020 Sep; 22(9):1359-1367. PubMed ID: 32034917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
